New bipartisan bill aims to curb U.S. biotech ties with China, but may miss key loophole
Congress is reviewing the Biotech Investment National Security Act, a bipartisan proposal to expand oversight of U.S. biotech activities and limit deals with Chinese firms, yet critics note a potential gap in the legislation.
Lawmakers are examining the bipartisan Biotech Investment National Security Act, a bill designed to tighten U.S. government oversight of everyday biotechnology work, from drug discovery to biologics manufacturing and clinical trials. The proposal, first introduced in June, expands the scope of the Comprehensive Outbound Investment National Security Act, which was enacted in December 2025. Its sponsors claim the added controls are essential for protecting national security interests in medical research, especially after Pfizer and Bristol Myers Squibb entered multibillion-dollar R&D and licensing deals with Chinese biotech firms.
In a press release, Representative John Moolenaar criticized those agreements as “dangerous” to the future of American pharmaceutical production. However, analysts note that the bill contains a loophole that could allow certain foreign collaborations to continue, potentially undermining its intended impact.
Why it matters
The legislation could reshape how U.S. biotech firms partner abroad, affecting national security and the pharmaceutical market.
In this story
